minimal invasive surgery for pancreatic insulinoma: current evidence dr. ho man-fung prince of wales...
TRANSCRIPT
Minimal invasive surgery for pancreatic insulinoma: Current evidence
Dr. HO Man-fung
Prince of Wales Hospital
CURRENT TREATMENT
Medical therapy
Dietary modification Diazoxide Somatostatin analogue
Minimal effect on disease progression (especially for non-responder)
Pre-operative symptoms control
Surgery
Surgery is the Mainstay of treatment for insulinoma Curative (local disease / limited liver metastasis) Symptomatic control in metastastic disease
Enucleation Distal pancreatectomy +/- splenectomy Pancreaticoduodenectomy Central / total pancreatectomy Resection of liver metastasis
Special concerns of insulinoma
Small size < 2cm in ~ 80% Difficulty in localization
90% benign and solitary Resection strategy Room for minimal invasive surgery
Overt symptoms, poorly controlled by drugs Pre-operative control of symptoms Even palliative resection in metastatic disease wound be
beneficial
Surgical approach
Pre-operative localization IOUS Enucleation or Pancreatectomy ? Blind distal pancreatectomy
Lo et al. Surgical Endoscopy (2004) 18: 297-302 60% with CT, 80% with EUS, 100% with THPVS
K. Ravi et al. Ann R Coll Surg Engl 2007; 89: 212-217. 67% (incl. USG, CT, MRI, THPVS)
Mehrdad Nikfarjam et al. Annals of Surgery • Volume 247, Number 1, January 2008 29-80% with non invasive investigation, 85-100% with invasive
investigations
Surgical approach
Pre-operative localization IOUS Enucleation or Pancreatectomy ? Blind distal pancreatectomy
Ref: A Fuller Understanding of Pancreatic Neuroendocrine Tumours Combined with Aggressive Management Improves Outcome. S.L.Ong et al. Pancreatology 2009;9:583–600
Amelia C. Grover et al. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery 2005; 138:1003-8
See the difficulties?
Ref: The American association of endocrine surgeons.Pancreatic neuroendocrine tumors: insulinoma
Surgical approach
Pre-operative localization IOUS Enucleation or Pancreatectomy ? Blind distal pancreatectomy
Enucleation Solitary lesion Size < 2cm Away from major vessels / pancreatic ducts
Pancreatectomy Multifocal lesions Size > 2cm Close to major vessels / pancreatic ducts MEN 1
Ref: L.Fernandez-Cruz et al. Is laparoscopic ressection adequate in patients with neuroendocrine pancreatic tumour. World Journal of Surgery (2008) 32: 904-917.
Surgical approach
Pre-operative localization IOUS Enucleation or Pancreatectomy ? Blind distal pancreatectomy
? Blind resection•4/61 persistent symptoms despite resection
•Further resection jeopadized parachymal preservation (90% benign)
•Importance of pre-operative localization
•Portal venous sampling (~100% localization)
Ref: Improved Contemporary Surgical Management of Insulinomas. A 25-year Experience at the Massachusetts General Hospital. Mehrdad Nikfarjam et al. Annals of Surgery • Volume 247, Number 1, January 2008
K. Ravi et al. Ann R Coll Surg Engl 2007; 89: 212-217.
Management of liver metastasis
Resection Transarterial chemoembolization Ablation Systemic chemotherapy Targeted therapy(e.g. Sunitinib,
everolimus) Liver transplantation
MINIMAL INVASIVE SURGERY
Lapasroscpic pancreatic resection 1st laparoscopic pancreatic resection -1992
Gagner M et al (1996). J Gastrointest Surg 1: 20-26 Cushieri A. et al (1996). Ann Surg 223:280-285
1st laparoscopic resection of insulinoma – 1992
Low incidence and difficult anatomical location, laparoscopic experience published relatively late compared to other laparoscopic surgery
2 enucleations and 2 distal pancreatectomies done laparoscopically
100% pre-operative localization Only for lesions over body and tail 1 patient with post operative pancreatic leakage
1st comparative study of laparoscopic vs open approach (12 vs 9)
Comparison with historical cohort No significant difference in morbidty, mortality,
intraoperative variables Only 1 patient used intra-operative USG Denied use of intra-operative USG to be
necessary
Laparoscopic USG Only way to replace palpation in laparoscopic
surgery
Localization of lesion(s) Sensitivity 83-98%a
Comparable to THPVS b
Define anatomical relationship with major vessels, main pancreatic duct
a) Mehrdad Nikfarjam et al . Improved Contemporary Surgical Management of Insulinomas. A 25-year Experience at the Massachusetts General Hospital.. Annals of Surgery • Volume 247, Number 1, January 2008
b) Amelia C. Grover et al. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery 2005; 138:1003-8
pNETs with pancreatic resection, 20 patients with insulinoma
Pre-op localization 100% 1/20 conversion to open Mean follow up of 36 months, no recurrence Significant less blood loss and operative time for
laparoscopic enucleation
21 patients Pre-operative localization - unknown 1/21 converted open IOUS: localization, intraoperative decision, marking
of transection line 3 patients with pancreatic fistula All except 1 discharged in 1 week No recurrence
89 patients (Lap vs open : 43 vs 46) 100% pre-operative localization
Whipple’s operation
Distal pancreatectomy
Enucleation
Number of patients 85 496 101
Mortality (%) 3.5 0.4 0
Mobidity (%) 30.7 34.1 47
Mean blood lost (ml) 126 311 -
Conversion rate (%) 8.75 12.1 23.3
Mean operation time (min)
371 229 132
Mean hospital stay 13.6 7.5 7.8
Represent early experience Highly selected cases Indicating minimal invasive surgery is feasible Pancreatic fistula is still the most prevalent
complication Lacking of long term results, e.g. survival,
recurrence Heterogeneous disease
Total n= 1814 (18 studies)
Laparoscopic arm (LDP): 773 (43%) Open arm : 1041 (57%)
Conversion rate : 0 – 30% (not reported in 4 studies)
Operative parameters: Blood loss
Post operative recovery: Length of stay
Post operative complications: pancreatic fistula
Laparoscopic distal pancreatectomy has the advantage of:Lower blood lossFaster recoveryComparable complication profile with open approach
This technique is a reasonable approach in selected cancer patients
What about robots?
1st 30 cases in University of Pittsburgh Compared with 94 patient with laparoscopic
distal pancreatectomy 0% conversion rate 100% R0 resection Median LN harvest (Lap vs Robot = 9 vs 19)
v
Better visualization, freedom of movement, stability Preservation of spleen and splenic vessels 21/22 patient with successful splenic preservation 17 patient with splenic vessels preserved 1 patient developed post op splenic infarct
Further expand the advantage minimal invasive surgery by improving rate of spleen preservation
Open vs Laparoscopic / robotic Whipple’s operation
Open vs Laparoscopic / robotic distal pancreatectomy
Longer operative time Decreased blood lost Shorter hospital stay Similar complication profile Improved rate of R0 resection
Robotic pancreatic surgery
Literature in its infancy Small cohort available
even for high volume centres
Case selection bias Learning curve Long term results
Local ablative therapy
Percutaneous RFA ablation Stephan Limer et al. European Journal of
Gastroenterology and Hepatology 2009, 21:1097-1101
EUS Guided ablation of insulinoma: a new treatment option Michael J. Levy et al. gastrointestinal Endoscopy, Vol
75, No.1;200-206
Conclusion
Insulinoma is benign most of the time, but causing significant biochemical disturbance that require surgical treatment
Localization is of utmost importance in surgical success
Laparoscopic surgery offers treatment with less trauma and similar safety profile
Novel treatment for surgically unfit individuals
Conclusion
Insulinoma is an ideal entity for minimal invasive pancreatic surgery
Lesion are small and benign most of the time no concern for involved margin, lymphatic dissection
Laparoscopic and robotic pancreatic surgery is feasible for management of pancreatic insulinoma
INSULINOMA
Insulinoma
Subgroup of pancreatic neuroendocrine tumours (pNETs)
Commonest functional pNETs (25%) Incidence : 4 in 1,000,000 Unsuppressed production of endogenous
insulin As part of genetic syndromes (5-8%)
MEN I, VHL, NF I, TS
Presentation
Whipple’s triad: Fasting hypoglycaemia (< 2.2 mmol/L)Symptomatic hypoglycaemia (autonomic and
neuroglycaemic symptoms)Relieve of symptoms after administration of
glucose Weight gain Other related syndromes
Biochemical diagnosis
Ref: A Fuller Understanding of Pancreatic Neuroendocrine Tumours Combined with Aggressive Management Improves Outcome. S.L.Ong et al. Pancreatology 2009;9:583–600
Localization Non-invasive
UltrasounographyComputed tomographyMagnetic resonance imagingSomatostatin receptor scintigraphy
Localization Invasive
Selective arteriographyTranshepatic portal venous
sampling +/- calcium stimulationSurgical exploration + intra-
operative US (IOUS)
Endoscopic ultrasound +/- FNAC
Ref: A Fuller Understanding of Pancreatic Neuroendocrine Tumours Combined with Aggressive Management Improves Outcome. S.L.Ong et al. Pancreatology 2009;9:583–600
WHO classification
Ref: A Fuller Understanding of Pancreatic Neuroendocrine Tumours Combined with Aggressive Management Improves Outcome. S.L.Ong et al. Pancreatology 2009;9:583–600
Ref: L.Fernandez-Cruz et al. Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumour. World Journal of Surgery (2008) 32: 904-917.